Skip to content
Precision for Medicine
Contact Us
AdobeStock_171759632 AdobeStock_171759632

Global Immune Monitoring Solutions

Industry-leading array of comprehensive immune monitoring solutions

Precision provides comprehensive immune monitoring services, from the development of customized assays for early clinical studies to managing the logistical and immune monitoring testing needs of global, registrational trials. We leverage multiple technology platforms on a global scale, including proprietary innovations like Epiontis ID®.

Unraveling the complexities of immunity: tailored solutions for detailed insights

  • Explore

    Flow Cytometry

    Standard and spectral flow cytometry, on both research-grade and CLIA-validated instruments
    Explore
  • Explore

    Epiontis ID® Epigenetic Cell Profiling

    Precision’s proprietary immune monitoring technology which delivers robust, repeatable, and cost-effective immune cell phenotyping on any sample type
    Explore
  • Explore

    Cytokine Profiling & Proteomics

    Customized assays to detect cytokines or proteins of interest utilizing ELISA, Luminex, MSD, SIMOA, and Western Blotting

    Explore
  • Explore

    ELISpot and Fluorospot

    ELISpot and FluoroSpot - including custom assays in support of gene therapy immunogenicity - from preclinical through clinical development

    Explore
  • Explore

    Cell-Based Assays

    Developing and qualifying 2D and 3D human in vitro cell-based models using a broad range of human primary cell types, with analysis enabling a variety of endpoints
    Explore
  • Explore
    companion-diagnostic

    Gene Expression Profiling of Biopsies

    Understand target expression, adaptive and innate immune responses at the gene expression level. Technologies we use for gene expression profiling include NanoString, Illumina RNA-seq, ddPCR, and qPCR.

    Explore

Efficient sample management logistics enable global immune monitoring services

Precision’s immune monitoring services are strengthened by a global logistics network, designed to safeguard sample integrity and maximize data reliability.

Clinical Reach

Global clinical sample and PBMC processing

  • Global PBMC processing in 24-hours or less
  • Regular competency assessment and monitoring to ensure site-to-site and lab-to-lab data comparability
  • Long- and short-term storage at optimal temperatures

Clinical sample logistics and biostorage

We have a 100,000 sq. ft. biorepository, which includes our 140,000 sq. ft. campus in Frederick, Maryland, and our global logistics and biobanking facilities in Berlin, Germany. This extensive network was the first to receive CAP certification. Currently, we are responsible for the storage of >20 million biospecimens under controlled conditions. We can accommodate any type of fluid or solid biological specimen at controlled ambient temperatures, +4℃, -20℃, -80℃, or in liquid nitrogen vapor.

The biorepository includes numerous security and safety features:

  • Redundant back-up systems, dedicated back-up units
  • Around-the-clock automated temperature monitoring
  • In-house HVAC technicians, specializing in cascade refrigeration

Unlocking potential: flow cytometry for breakthrough research

Precision for Medicine offers a suite of flow cytometry services tailored to the intricate demands of modern scientific research and therapeutic development

Brochure

High-Content Flow Cytometry

Download Brochure
High-Content Flow Cytometry

Epiontis ID® - Optimized Immune Profiling

Within our suite of immune monitoring services, Epiontis ID® proprietary technology stands out by offering an epigenetic approach to cell profiling. See how it works.

Explore

Related resources

Blog - Ut libero urna, finibus sed tortor nec, fringilla blandit est

Nullam fermentum, massa vel lacinia pellentesque, nulla erat condimentum ipsum, ac blandit sapien neque sed sem. Quisque bibendum semper erat, nec luctus ligula.

Visit blog
Read: Case Study: Rescue of a Global Phase 3 Trial in Multiple Myeloma Case Study: Rescue of a Global Phase 3 Trial in Multiple Myeloma

Case Study: Rescue of a Global Phase 3 Trial in Multiple Myeloma

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548848, hs_child_table_id=0, hs_updated_at=1754641451547, hs_published_at=1757700235512, description=Alexis Hobbins-White is an accomplished leader who plays a pivotal role in navigating the complex landscape of global oncology and rare disease-focused clinical trials. With a career spanning over 15 years in the clinical trials industry, Alexis brings a wealth of experience across multiple therapeutic areas, showcasing her proficiency in diverse aspects of operational strategy. She specializes in early phase adaptive studies, particularly in immuno-oncology and advanced therapeutics. She has an MSc in Neuroscience and an MA in Biotechnology Law and Ethics., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Alexis-Hobbins.png',altText='Alexis-Hobbins',fileId=194096322982}, linkedin=https://www.linkedin.com/in/alexis-hobbins-white-400a1720/, lastname=Hobbins-White, hs_initial_published_at=1713362276020, hs_created_by_user_id=5166971, hs_created_at=1713361952861, hs_is_edited=false, hs_deleted_at=0, name=Alexis, job=Senior Director, Operational Strategy , slug=alexis-hobbins-white, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Alexis Hobbins-White avatar

    Alexis Hobbins-White
Discover
Read: FDA Draft Guidance on Overall Survival in Oncology Trials – What Sponsors Need to Know FDA Draft Guidance on Overall Survival in Oncology Trials – What Sponsors Need to Know

Clinical Trials - Regulatory - Oncology

FDA Draft Guidance on Overall Survival in Oncology Trials – What Sponsors Need to Know

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=195804116748, hs_child_table_id=0, hs_updated_at=1757700176991, hs_published_at=1757700235512, description=John is an experienced regulatory affairs consultant with more than 15 years of professional experience in drug development. He brings a proven track record in providing regulatory strategy, regulatory document development and review, and liaising with regulatory authorities., avatar=Image{width=1000,height=1000,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/John%20McIntyre.jpg',altText='John McIntyre',fileId=195809756215}, lastname=McIntyre, PhD, hs_initial_published_at=1757516163742, hs_created_by_user_id=26433386, hs_created_at=1757515873736, hs_is_edited=false, hs_deleted_at=0, name=John, job=Senior Director, Regulatory Strategy, slug=john-mcintyre, hs_updated_by_user_id=26433386}, second={hs_id=195804116749, hs_child_table_id=0, hs_updated_at=1757598950007, hs_published_at=1757700235512, description=An expert in hematology and oncology and a veteran of the FDA with almost nine years of experience, culminating as a Deputy Director for the Division of Hematologic Malignancies 2. Possesses a profound understanding of regulatory strategy, particularly in the development of CAR-T cell therapies, bispecifics and T-cell engagers. Spearheaded initiatives to develop novel endpoints in blood cancer such as minimal residual disease (MRD) in lymphoma and chronic lymphocytic leukemia (CLL.), avatar=Image{width=1000,height=1000,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Nick%20Richardson.jpg',altText='Nick Richardson',fileId=195807970451}, linkedin=https://www.linkedin.com/in/nicholas-richardson-do-mph-049784113/, lastname=Richardson, DO, MPH, hs_initial_published_at=1757516163742, hs_created_by_user_id=26433386, hs_created_at=1757516077087, hs_is_edited=false, hs_deleted_at=0, name=Nick, job=Vice President, Clinical Development, slug=nick-richardson, hs_updated_by_user_id=26433386}, third={}})
  • John M. avatar

    John M.
  • Nick R. avatar

    Nick R.
Discover
Read: How AI & Biomarkers Are Reshaping the Next Frontier in Drug Development How AI & Biomarkers Are Reshaping the Next Frontier in Drug Development

Translational Research - Biomarkers - Oncology

How AI & Biomarkers Are Reshaping the Next Frontier in Drug Development

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778858, hs_child_table_id=0, hs_updated_at=1754641583843, hs_published_at=1757700235512, description=Rob Maiale is a marketing strategist and creative technologist with 17 years of experience turning complex ideas into growth. He currently leads content strategy, where he transforms insights from Precision experts into market-shaping narratives that drive the advancement of next-generation therapies.  Rob’s career spans journalism, advertising, and brand storytelling, with a through-line of making the meaningful memorable. His work blends creative strategy with emerging AI tools to help Precision stay ahead of the curve—and above the noise., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/rob.png',altText='rob',fileId=194099000843}, linkedin=https://www.linkedin.com/in/rob-maiale/, hs_name=, hs_path=, lastname=Maiale, hs_initial_published_at=1757516479594, hs_created_at=1709645745089, hs_is_edited=false, hs_deleted_at=0, name=Rob, position=Associate Director, Digital Content & Inbound Marketing, job=, slug=rob-maiale, email=, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Rob Maiale avatar

    Rob Maiale
Discover